Recent Advances in Cancer Treatment Drugs: The Developmental Journey from Preclinical Discovery to Market Approval
Main Article Content
Abstract
The oncology landscape is undergoing a profound paradigm shift from broad-spectrum cytotoxic chemotherapies to highly selective, mechanism-driven precision medicine. This report systematically reviews the structural development, validation pathways, and regulatory mechanisms of next-generation oncology therapeutics. Modern precision oncology focuses on the targetable oncogenic drivers of malignant transformation—including epidermal growth factor receptor (EGFR) exon 20 insertions, human epidermal growth factor receptor 2 (HER2) mutations, Kirsten rat sarcoma virus oncogene (KRAS) G12C, and estrogen receptor 1 (ESR1) mutations—via small-molecule kinase inhibitors, antibody-drug conjugates (ADCs) featuring stable linkers and topoisomerase I payloads, and proteolysis-targeting chimeras (PROTACs). We highlight clinical milestones and regulatory approvals from 2025 and 2026, including the landmark PROTAC vepdegestrant, bispecific antibodies such as zenocutuzumab, and novel combinations like teclistamab with daratumumab.
Preclinical validation has evolved through three-dimensional patient-derived organoids (PDOs) and patient-derived xenograft (PDX) mouse models to characterize pharmacokinetic and pharmacodynamic profiles with high translational fidelity. In clinical phases, innovative dose-escalation strategies, such as accelerated titration and adaptive master protocols, including basket, umbrella, and platform designs, have accelerated efficacy evaluations. These designs are increasingly optimized through artificial intelligence (AI), utilizing machine learning for biomarker stratification, patient matching, and the generation of synthetic control arms. Finally, this review highlights the transition toward personalized oncology vaccines, such as mRNA-based intismeran autogene, and completely customized multi-targeted drug regimens. This synthesized analysis outlines how the convergence of structural biology, computational oncology, and flexible regulatory frameworks is fundamentally accelerating the transition of highly selective oncology drugs from bench to bedside.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Falzone, Luca, Salvatore Salomone, and Massimo Libra. 2018. “Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.” Frontiers in Pharmacology 9 (1300). https://doi.org/10.3389/fphar.2018.01300.
II. Doroshow, Deborah B., and James H. Doroshow. 2019. “From the Broad Phase II Trial to Precision Oncology.” The Cancer Journal 25 (4): 245–53. https://doi.org/10.1097/ppo.0000000000000386.
III. Lim, Zuan-Fu, and Patrick C. Ma. 2019. “Emerging Insights of Tumor Heterogeneity and Drug Resistance Mechanisms in Lung Cancer Targeted Therapy.” Journal of Hematology & Oncology 12 (1). https://doi.org/10.1186/s13045-019-0818-2.
IV. Burrell, Rebecca A., and Charles Swanton. 2014. “Tumour Heterogeneity and the Evolution of Polyclonal Drug Resistance.” Molecular Oncology 8 (6): 1095–1111.
https://doi.org/10.1016/j.molonc.2014.06.005.
V. Tomić, Krešimir, and Semir Vranić. 2026. “A Remarkable Year for NSCLC: Seven New FDA Approvals in 2025 across Molecular Targets.” Biomolecules and Biomedicine 26 (6): 869–71. https://doi.org/10.17305/bb.2026.13832.
VI. Cancer. 2026. “FDA Approvals in Oncology: January-March 2026.” American Association for Cancer Research (AACR). April 2026. https://www.aacr.org/blog/2026/04/01/fda-approvals-in-oncology-january-march-2026/.
VII. Chour, Ali, Anne-Claire Toffart, Elodie Berton, and Michael Duruisseaux. 2024. “Mechanisms of Resistance to KRASG12C Inhibitors in KRASG12C-Mutated Non-Small Cell Lung Cancer.” Frontiers in Oncology 14 (September). https://doi.org/10.3389/fonc.2024.1328728.
VIII. Blaquier, Juan Bautista, Andrés Felipe Cardona, and Gonzalo Recondo. 2021. “Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer.” Frontiers in Oncology 11 (December). https://doi.org/10.3389/fonc.2021.787585.
IX. “Targeting ER Mutations and Drug Resistance - WuXi Biology.” 2026. WuXi Biology. May 28, 2026. https://wuxibiology.com/?post_type=resource&p=9824.
X. Martinez, Thais, Samantha Wegner, and Hisham F. Bahmad. 2026. “ESR1 Mutations in ER-Positive Breast Cancer: From Endocrine Resistance to CtDNA-Guided Therapeutic Interception.” Exploration of Targeted Anti-Tumor Therapy 7 (May).
https://doi.org/10.37349/etat.2026.1002375.
XI. Wang, Zixi, Yurou Xing, Bingjie Li, Xiaoyu Li, Bin Liu, and Yongsheng Wang. 2022. “Molecular Pathways, Resistance Mechanisms and Targeted Interventions in Non-Small-Cell Lung Cancer.” Molecular Biomedicine 3 (1).
https://doi.org/10.1186/s43556-022-00107-x.
XII. Jiang, Kuikui, and Shusen Wang. 2026. “Advances in TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer Therapy: Into the New Era.” Cancer Biology & Medicine 23 (3): 327–37. https://doi.org/10.20892/j.issn.2095-3941.2025.0504.
XIII. “ADC Drugs by Target in 2026: 21 Approved ADCs List.” 2026. DengYueMed. March 17, 2026. https://dengyuemed.com/blog/adc-drugs-by-target-in-2026/.
XIV. PatSnap. 2026. “ERα Degradation Efficiency: Vepdegestrant vs. Elacestrant vs. Fulvestrant in ESR1-Mutant Models.” PatSnap. April 23, 2026. https://www.patsnap.com/resources/blog/ls-blog/vepdegestrant-protac-er-degrader-fda-filing-patsnap-eureka/.
XV. Bai, Nan, Sven A. Miller, Grigorii V. Andrianov, Max Yates, Palani Kirubakaran, and John Karanicolas. 2021. “Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.” Journal of Chemical Information and Modeling 61 (3): 1368–82.
https://doi.org/10.1021/acs.jcim.0c01451.
XVI. Girardini, Miriam, Chiara Maniaci, Scott J. Hughes, Andrea Testa, and Alessio Ciulli. 2019. “Cereblon versus VHL: Hijacking E3 Ligases against Each Other Using PROTACs.” Bioorganic & Medicinal Chemistry 27 (12): 2466–79. https://doi.org/10.1016/j.bmc.2019.02.048.
XVII. “Ternary Complex Formation.” 2026.
Promega.com. 2026.
XVIII. Wu, Kingsley Y, Ta I Hung, and Chia-en A Chang. 2024. “PROTAC-Induced Protein Functional Dynamics in Targeted Protein Degradation.” BioRxiv (Cold Spring Harbor Laboratory), September. https://doi.org/10.7554/elife.101127.1.
XIX. Konstantinidou, Markella, Jingyao Li, Bidong Zhang, Zefeng Wang, Shabnam Shaabani, Frans Ter Brake, Khaled Essa, and Alexander Dömling. 2019. “PROTACs– a Game-Changing Technology.” Expert Opinion on Drug Discovery 14 (12): 1255–68.
https://doi.org/10.1080/17460441.2019.1659242.
XX. Katya Mameishvili, Ph.D. 2025. “3D Organoids vs 2D Cell Lines in Drug Discovery and Disease Modeling.” Biocompare.com. May 20, 2025. https://www.biocompare.com/Editorial-Articles/619144-3D-Organoids-vs-2D-Cell-Lines-in-Drug-Discovery-and-Disease-Modeling/.
XXI. Zhang, Yizheng, Naray Payab, Bettina Weigelin, and Christian M. Schürch. 2026. “From 2D Cultures to 3D Systems: Evolving Cancer Models at the Interface of Functional Precision Medicine and Theranostics.” Theranostics 16 (8): 4042–57. https://doi.org/10.7150/thno.127053.
XXII. Suarez-Martinez, Elisa, Irene Suazo-Sanchez, Manuel Celis-Romero, and Amancio Carnero. 2022. “3D and Organoid Culture in Research: Physiology, Hereditary Genetic Diseases and Cancer.” Cell & Bioscience 12 (April): 39. https://doi.org/10.1186/s13578-022-00775-w.
XXIII. Powley, Ian R., Meeta Patel, Gareth Miles, Howard Pringle, Lynne Howells, Anne Thomas, Catherine Kettleborough, et al. 2020. “Patient-Derived Explants (PDEs) as a Powerful Preclinical Platform for Anti-Cancer Drug and Biomarker Discovery.” British Journal of Cancer 122 (6): 735–44. https://doi.org/10.1038/s41416-019-0672-6.
XXIV. Braun, Rüdiger, and Hendrik Ungefroren. 2023. “Preclinical Patient-Derived Culture Models for Personalized Treatment of Pancreatic Cancer: A Dream of the Future or Useful Practice?” Cancers 15 (11): 3027–27.
https://doi.org/10.3390/cancers15113027.
XXV. Study Details | NCT05116709 | Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors | ClinicalTrials.gov, accessed June 8, 2026, https://clinicaltrials.gov/study/NCT05116709
XXVI. Wei, Lai, Xueliang Pan, and Soledad Fernandez. 2019. “Practical Considerations for the Implementation of Adaptive Designs for Oncology Phase I Dose-Finding Trials.” Future Drug Discovery 1 (2).
https://doi.org/10.4155/fdd-2019-0021.
XXVII. Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials - PMC, accessed June 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6811732/
XXVIII. Paoletti, X, M. Ezzalfani, and C. Le Tourneau. 2015. “Statistical Controversies in Clinical Research: Requiem for the 3 + 3 Design for Phase I Trials.” Annals of Oncology 26 (9): 1808–12. https://doi.org/10.1093/annonc/mdv266.
XXIX. Le Tourneau, Christophe, Hui K. Gan, Albiruni R. A. Razak, and Xavier Paoletti. 2012. “Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents.” PLoS ONE 7 (12).
https://doi.org/10.1371/journal.pone.0051039.
XXX. Park, Jay J. H., Grace Hsu, Ellie G. Siden, Kristian Thorlund, and Edward J. Mills. 2020. “An Overview of Precision Oncology Basket and Umbrella Trials for Clinicians.” CA: A Cancer Journal for Clinicians 70 (2): 125–37. https://doi.org/10.3322/caac.21600.
XXXI. Basket vs. Umbrella Trials: Master Protocols Explained - IntuitionLabs, accessed June 8, 2026, https://intuitionlabs.ai/articles/basket-vs-umbrella-trials
XXXII. May 2026: FDA Oncology Actions at a Glance | Targeted Oncology ..., accessed June 8, 2026, https://www.targetedonc.com/view/may-2026-fda-oncology-actions-at-a-glance
XXXIII. Park, Jay J. H, Ellie Siden, Michael J. Zoratti, Louis Dron, Ofir Harari, Joel Singer, Richard T. Lester, Kristian Thorlund, and Edward J. Mills. 2019. “Systematic Review of Basket Trials, Umbrella Trials, and Platform Trials: A Landscape Analysis of Master Protocols.” Trials 20 (1). https://doi.org/10.1186/s13063-019-3664-1.
XXXIV. Basket trials in rare diseases: a systematic review of current practices, methodological challenges, and future directions - PMC, accessed June 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12613744/
XXXV. Evolving Trial Designs Advance Precision Medicine Through Basket, Umbrella, and Platform Models | Applied Clinical Trials Online, accessed June 8, 2026,
XXXVI. Kolla, Likhitha, Fred K Gruber, Omar Khalid, Colin Hill, and Ravi B Parikh. 2021. “The Case for AI-Driven Cancer Clinical Trials – the Efficacy Arm in Silico.” Biochimica et Biophysica Acta - Reviews on Cancer 1876 (1): 188572–72.
https://doi.org/10.1016/j.bbcan.2021.188572.
XXXVII. AI in Clinical Development Plans: Methods & Impact | IntuitionLabs, accessed June 8, 2026,
https://intuitionlabs.ai/articles/ai-clinical-development-plans-trials
XXXVIII. Will synthetic control arms revolutionize clinical trials? - Servier, accessed June 8, 2026,
https://servier.com/en/newsroom/synthetic-control-arms-revolutionize-clinical-trials/
XXXIX. How can synthetic control arms transform clinical trials? We go into detail on the implementation of AI in disease detection - Quibim, accessed June 8, 2026, https://quibim.ai/news/synthetic-control-arm-in-clinical-studies/
XL. Jørgensen, Jan Trøst. 2026. “FDA 2025 Cancer Drug Approvals: Targeted Therapy Dominates.” Exploration of Targeted Anti-Tumor Therapy 7
(April). https://doi.org/10.37349/etat.2026.1002369.
XLI. ADC Pipeline Update: Four Antibody-Drug Conjugates Designated in February 2026, accessed June 8, 2026,
https://www.patsnap.com/resources/blog/articles/adc-pipeline-february-2026/
XLII. “Genentech: Press Releases | FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD with Positive Phase III Results in the Curative Setting.” 2026. Gene.com. 2026. https://www.gene.com/media/press-releases/15115/2026-06-01/fda-accepts-new-drug-application-for-gen.
XLIII. FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting, accessed June 8, 2026,
https://www.roche.com/media/releases/med-cor-2026-06-02
XLIV. Novel Drug Approvals for 2025 | FDA, accessed June 8, 2026, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
XLV. Oncology (Cancer)/Hematologic Malignancies Approval Notifications - FDA, accessed June 8, 2026, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
XLVI. Novel Drug Approvals for 2026 - FDA, accessed June 8, 2026, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
XLVII. Breast Cancer Breakthroughs Episode 21: Real World Impact of Oral SERDs, accessed June 8, 2026, https://www.komen.org/blog/bcbt-real-world-impact-oral-serds/
XLVIII. Akhave, Neal S., Amadeo B. Biter, and David S. Hong. 2021. “Mechanisms of Resistance to KRASG12C-Targeted Therapy.” Cancer Discovery 11 (6): 1345–52.
https://doi.org/10.1158/2159-8290.cd-20-1616.
XLIX. FDA-Approved Oncology Therapies - OncoKB, accessed June 8, 2026,
https://www.oncokb.org/oncology-therapies
L. Tanaka, Noritaka, and Hiromichi Ebi. 2024. “Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells’ Strategic Use of Normal Cellular Mechanisms to Adapt.” Cancer Science, December. https://doi.org/10.1111/cas.16441.
LI. Li, Yiyang, Zixuan Liu, Benliang Yuan, Tianshuai Zhang, Xiaoming Zhu, Leqi Zhou, Wei Zhang, and Guanyu Yu. 2026. “Liquid Biopsy in Cancer Drug Resistance: Real-Time Monitoring, Mechanistic Insights, and Translational Applications.” Frontiers in Immunology 17 (April). https://doi.org/10.3389/fimmu.2026.1795789.
LII. Fang, Xiaoxu, Shaokun Yu, Yingying Jiang, Yan Xiang, and Kaihua Lu. 2022. “Circulating Tumor DNA Detection in MRD Assessment and Diagnosis and Treatment of Non-Small Cell Lung Cancer.” Frontiers in Oncology 12: 1027664. https://doi.org/10.3389/fonc.2022.1027664.
LIII. Gianna Di Sario, Valeria Rossella, Elvira Smeralda Famulari, Aurora Maurizio, Dejan Lazarević, Francesca Giannese, and Claudia Felici. 2023. “Enhancing Clinical Potential of Liquid Biopsy through a Multi-Omic Approach: A Systematic Review.” Frontiers in Genetics 14 (April). https://doi.org/10.3389/fgene.2023.1152470.
LIV. Circulating Tumor DNA (ctDNA) Testing to Predict Response in Solid Tumors, accessed June 8, 2026,
LV. Integrating AlphaFold into the Drug Discovery Process - Creative Biostructure, accessed June 8, 2026, https://www.creative-biostructure.com/integrating-alphafold-drug-discovery.htm
LVI. AlphaFold Meets De Novo Drug Design: Leveraging Structural ..., accessed June 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11558674/
LVII. The Isomorphic Labs Drug Design Engine unlocks a new frontier ..., accessed June 8, 2026, https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier
LVIII. Fayyaz, Amna, Aleena Haqqi, Rashid Khan, Muhammad Irfan, Khushbukhat Khan, Željko Reiner, Javad Sharifi-Rad, and Daniela Calina. 2024. “Revolutionizing Cancer Treatment: The Rise of Personalized Immunotherapies.” Discover Oncology 15 (1). https://doi.org/10.1007/s12672-024-01638-1.
LIX. Fnu Rukhayya, Lahari Katta, Hana Khan Ghori, Shreya Kattela, Maahin Parvez, Sarojini Posani, Mihirkumar P Parmar, Fnu Jatin, Sweta Sahu, and Salma Younas. 2025. “Personalized Cancer Vaccines in Combination Therapies: Current Status and Future Prospects.” Asian Pacific Journal of Cancer Prevention 26 (8): 2741–54. https://doi.org/10.31557/apjcp.2025.26.8.2741.
LX. Stefano Zoroddu, and Luigi Bagella. 2025. “Next-Generation MRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies.” Cells 14 (18): 1476–76. https://doi.org/10.3390/cells14181476.
LXI. Debela, Dejene Tolossa, Seke GY Muzazu, Kidist Digamo Heraro, Maureen Tayamika Ndalama, Betelhiem Woldemedhin Mesele, Dagimawi Chilot Haile, Sophia Khalayi Kitui, and Tsegahun Manyazewal. 2021. “New Approaches and Procedures for Cancer Treatment: Current Perspectives.” SAGE Open Medicine 9 (9): 205031212110343. https://doi.org/10.1177/20503121211034366.